Figure 4a. Forest plot for the outcome of hospitalizations for casirivimab/imdevimab vs. no casirivimab/etesevimab (data for 1200-mg dose only) [1]

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M–H, Fixed, 95% CI	Risk Ratio M–H, Fixed, 95% CI
Weinreich 2021 (1200)	6	736	23	748	100.0%	0.27 [0.11, 0.65]	
Total (95% CI)		736		748	100.0%	**0.27 [0.11, 0.65]**	
Total events	6		23				
Heterogeneity: Not applicable							
Test for overall effect: Z = 2.91 (P = 0.004)							

Reference

1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med **2021**; 384(3): 238-51.